Caan, Bette J Meyerhardt, Jeffrey A Brown, Justin C Campbell, Kristin L Cespedes Feliciano, Elizabeth M Lee, Catherine Ross, Michelle C Quinney, Sara Quesenberry, Charles Sternfeld, Barbara
...
Published in
Contemporary clinical trials
Low muscle is associated with an increased risk of chemotherapy-related dose limiting toxicities (DLT) in cancer patients. Resistance training (RT) improves muscle mass; however, the effects of RT on preventing DLTs and dose reductions in colon cancer patients has not been investigated. FOcus on Reducing dose-limiting toxicities in Colon cancer wit...
Retornaz, Frédérique Guillem, Olivier Rousseau, Frédérique Morvan, Francois Rinaldi, Yves Nahon, Sophie Castagna, Chantal Boulahssass, Rabia Grino, Michel Gholam, Dany
...
Published in
The Oncologist
Colon cancer mainly affects older patients who are at risk for chemotherapy‐related toxicities. This article describes the ColonPrediscores system for identifying patients with in increased risk for toxicity and/or death in this patient group.
Couderc, Anne-Laure Boulahssass, Rabia Nouguerède, Emilie Gobin, Nirvina Guérin, Olivier Villani, Patrick Barlesi, Fabrice Paillaud, Elena
Published in
Journal of geriatric oncology
Comprehensive Geriatric Assessment (CGA), is used in older patients with cancer to identify frailties, which can interfere with specialized treatment, and to help with therapeutic care. Functional Status (FS) is a domain of CGA in which Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) are evaluation tools. Our stu...
Rump, A Eder, S Lamkowski, A Hermann, C Abend, M Port, M
Published in
Toxicology letters
The radiotoxic effects of uranium are often in the focus of the public fears but the chemical toxic effects of uranium are reported to surpass radiation effects. As there is no uranium isotope that is not radioactive, it is not possible to study chemical effects fully independently from radiation effects. In order to quantitate and compare radio- a...
Wang, Tian Qi Samuel, Joseph N. Brown, M. Catherine Vennettilli, Ashlee Solomon, Hannah Eng, Lawson Liang, Mindy Gill, Gursharan Merali, Zahra Tian, Chenchen
...
Published in
Oncology and Therapy
IntroductionSystematic documentation of chemotoxicities in outpatient clinics is challenging. Incorporating patient-reported outcome (PRO) measures in clinical workflows can be an efficient strategy to strengthen the assessment of symptomatic treatment toxicities in oncology clinical practice. We compared the adequateness, feasibility, and acceptab...
Brayboy, Lynae M Oulhen, Nathalie Long, Sokunvichet Voigt, Niesha Raker, Christina Wessel, Gary M
Published in
Reproductive toxicology (Elmsford, N.Y.)
Ovarian protection from chemotoxicity is essential for reproductive health. Our objective is to determine the role of ATP-dependent, Multidrug Resistance Transporters (MDRs) in this protection. Previously we identified MDR-dependent cytoprotection from cyclophosphamide in mouse and human oocytes by use of MDR inhibitors. Here we use genetic deletio...
Knott, Kristopher Starling, Naureen Rasheed, Shahnawaz Foran, John Cafferkey, Catherine Rosen, Stuart Nicholson, Andrew Baksi, John Lyon, Alexander
Published in
International journal of cardiology
Popa, Mihaela A Wallace, Kristie J Brunello, Antonella Extermann, Martine Balducci, Lodovico
Published in
Journal of geriatric oncology
Increased risk of drug interactions due to polypharmacy and aging-related changes in physiology among older patients with cancer is further augmented during chemotherapy. No previous studies examined potential drug interactions (PDIs) from polypharmacy and their association with chemotherapy tolerance in older patients with cancer. This study is a ...
Russo, Giulia Cioffi, Giovanni Di Lenarda, Andrea Tuccia, Fausto Bovelli, Daniella Di Tano, Giuseppe Alunni, Gianfranco Gori, Stefania Faggiano, Pompilio Tarantini, Luigi
...
Published in
Internal and Emergency Medicine
Anthracyclines, taxanes and trastuzumab are used for therapy in early breast cancer (EBC) overexpressing Human Epidermal Growth Factor 2 (HER2+). These drugs, considered alone, do not present potential nephrotoxicity. However, renal dysfunction (RD) may increase the myocardial sensibility to the insult of these chemotherapies used in combination. T...
